SARTORIUS
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer and manufacturer Biological Industries. For approximately €45 million in cash, Sartorius is acquiring just over 50% of the shares of the company from its owners, Kibbutz Beit Haemek and private equity fund Fortissimo Capital. An option to acquire a further 20% of the shares within three years was also agreed. The transaction is subject to customary closing conditions and expected to be finalized by mid-December.
“By acquiring a majority stake in Biological Industries, we are significantly expanding our cell culture media offering and complementing our product portfolio for customers in the dynamically growing advanced therapies market,” commented Joachim Kreuzburg, CEO of the Sartorius Group.
Biological Industries focuses on cell culture media, particularly for cell and gene therapy, regenerative medicine and other advanced therapies. Founded in 1981, the company currently employs approximately 130 people mainly at its headquarters, R&D and manufacturing site close to Haifa, Israel, and at sales locations in the USA, Europe and China. Biological Industries has recorded significant revenue growth and expects to achieve sales of approximately €25 million with a double-digit operating EBITDA margin in the current year.
Cell culture media are used in research, clinical development and production of biopharmaceuticals as well as in cell and tissue therapy applications. The company offers complete media solutions including a strong portfolio of clinical-grade media for cultivating cells and stem cells and for cryopreservation, applications that are both particularly relevant in advanced therapy research and clinical development. In addition, Biological Industries provides cell culture reagents as well as classical and serum-free media.
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn .
A profile of Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has a track record of double digit growth rates and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, Sartorius earned sales revenue of around 1.57 billion euros. Currently, more than 8,800 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MUNDIPHARMA24.4.2024 22:02:28 CEST | Press release
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area
MA-BEIGENE24.4.2024 22:02:28 CEST | Press release
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
CA-TSMC24.4.2024 21:31:27 CEST | Press release
TSMC Celebrates 30th North America Technology Symposium with Innovations Powering AI with Silicon Leadership
NV-RIMINI-STREET-INC.24.4.2024 18:51:35 CEST | Press release
Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer
NY-HITHIUM24.4.2024 18:01:34 CEST | Press release
Hithium Hosts Roundtable at the BNEF Summit New York, Discussing Next Generation Battery Energy Storage System
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom